Reuters Health Information (2004-11-30): MRI-guided percutaneous cryotherapy effective for ablation of liver tumors Clinical
MRI-guided percutaneous cryotherapy effective for ablation of liver tumors
Last Updated: 2004-11-30 14:45:03 -0400 (Reuters Health)
By M. Mary Conroy
CHICAGO (Reuters Health) - Percutaneous cryotherapy
under magnetic resonance imaging guidance achieved an overall 49%
success rate in ablating liver tumors of 5 cm or less, according to
research reported at the 90th scientific assembly and annual meeting of
the Radiological Society of North America (RSNA).
Lead investigator Dr. Kemal Tuncali, an instructor in radiology at
Brigham and Women's Hospital in Boston, said the success rate was 62%
for smaller lesions (3.5 cm or less).
Dr. Tuncali said 34 patients with 47 liver tumors have been treated
using MRI-guided cryotherapy, and he reported results from a series of
31 patients with 44 lesions. "Most of the lesions were metastases from
aggressive cancers in the colon and other sites," he told Reuters
Health. "Only two of the lesions were hepatocellular cancers."
Sixteen of the patients were women and the mean age was 62. The mean lesion size was 2.9 cm.
"We were able to treat 39 of 44 lesions and 17 of those required only one treatment," Dr. Tuncali said.
The procedure involves "initial rapid freezing, which takes about 15
minutes, a thawing for 10 minutes and then a second rapid freezing for
15 minutes. We know that cells die with rapid freezing, then additional
death occurs with thawing, and finally the second freezing achieves
additional cell death."
Among the complications associated with the treatment were "a
transitory rise in bilirubin, a blood clot in the lung, liver bleeding,
a clotting problem and a cancer nodule recurrence under the skin," Dr.
Tuncali said. All complications responded to treatment and there were
no fatalities associated with treatment.
He noted that recovery time "was quick and most patients were discharged after 24 hours."
The overall survival rate at 15 months is 77% in the current series.
|